CV Sciences (CVSI) Liabilities and Shareholders Equity (2010 - 2026)

CV Sciences has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $6.7 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $6.7 million, down 13.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (down 13.15% YoY), and the FY2025 annual result was $7.0 million, down 12.17% from the prior year.
• Liabilities and Shareholders Equity came in at $6.7 million for Q1 2026 at CV Sciences, down from $7.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.3 million in Q1 2022 to a low of $6.7 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $8.9 million (2024), against an average of $10.1 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 43.34% in 2022 and declined 8.33% in 2025, its largest moves.
• CV Sciences' Liabilities and Shareholders Equity stood at $12.7 million in 2022, then fell by 27.76% to $9.2 million in 2023, then fell by 13.84% to $7.9 million in 2024, then retreated by 12.17% to $7.0 million in 2025, then declined by 3.45% to $6.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $6.7 million (Q1 2026), $7.0 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.